VivoSim Labs, Inc. (VIVS) Fair Value 2026

VIVS · Biological Products, (No Diagnostic Substances) ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.5 /10

32 fundamental signals · 9 models active

Value Trap Risk

WARN (51/100)

Quick Summary — As of 2026-07-15, VivoSim Labs, Inc. (VIVS) trades at $0.85, approximately 14% below CirclFi’s Bayesian DCF fair value of $0.99. QOC: 4.5/10. Value Trap Risk: 51/100 (WARN). 9/13 models active.

Key Facts

Ticker
VIVS
Price
$0.85
Quality Score
4.5/10
Value Trap Risk
51/100
Models Active
9/13
Last Updated
Strength: Earnings Power Value suggests +262.5% upside with 24% confidence
Risk: Value Trap score of 51 suggests caution despite apparent undervaluation

Is VivoSim Labs, Inc. (VIVS) Undervalued or Overvalued in 2026?

According to CirclFi’s 9-model valuation engine, VivoSim Labs, Inc. (VIVS) appears undervalued as of : the median of 9 independent fair value estimates is $1.40, 63.8% above the current price of $0.85. Estimates range from $0.94 to $3.09. VIVS scores 4.5/10 on fundamental quality and 51/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy VivoSim Labs, Inc. Stock in 2026? →

Valuation Matrix

9 Intrinsic Value Models vs. Current Price ($0.85)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $0.99 +16.0%
Earnings Power Value
Medium Conviction
 $3.09 +262.5%
CUCE Ensemble
Low Conviction
 $1.75 +105.7%
First Chicago
Medium Conviction
 $1.34 +57.3%

Unlock the Full Matrix

Access 5 additional models including Dynamic NAV, PWERM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 9 Models →

Cancel anytime · No contracts · Instant access

What Is VivoSim Labs, Inc. (VIVS) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, VivoSim Labs, Inc.'s intrinsic value is estimated at a composite fair value of $1.68. At a current market price of $0.85, 9 of 9 active valuation models identify upside potential, projecting an average implied return of +96.7%. Notably, EPV sees the most upside at +262.5% (fair value: $3.09), while PWERM is the most conservative at +9.7% ($0.94). The spread between these extremes — +252.8% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About VIVS?

9 of 13 models are currently active for VIVS. All 9 active models suggest the stock trades below fair value. The Bayesian DCF estimates VIVS's intrinsic value at $0.99, implying +16.0% upside from the current price. See which stocks rank higher →

How Does VIVS Rank in Biological Products, (No Diagnostic Substances)?

Among 134 Biological Products, (No Diagnostic Substances) stocks, VIVS ranks #95 by Quality of Company score. CirclFi's QOC score of 4.5/10 evaluates 32 fundamental signals. A score of 4.5 reflects mixed fundamentals.

See all Most Undervalued Biological Products, (No Diagnostic Substances) Stocks →

VivoSim Labs, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is VIVS a Value Trap?

CirclFi's Value Trap algorithm assigns VIVS a score of 51/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

9 of 13 models are active for VivoSim Labs, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, VivoSim Labs, Inc. earns a quality score of 4.5/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency. Our Value Trap detector shows moderate caution signals worth monitoring.

The gap between the most bullish and bearish model spans +252.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every VIVS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across VIVS's 9 active models, average confidence is 23%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy VivoSim Labs, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biological Products, (No Diagnostic Substances) Stocks Should You Also Analyze?

8 related Biological Products, (No Diagnostic Substances) stocks with 13-model coverage

EXELExelixis, Inc.QOC 10.0HALOHalozyme Therapeutics, Inc.QOC 10.0NBIXNeurocrine Biosciences, Inc.QOC 10.0GILDGilead Sciences, Inc.QOC 9.7PLXProtalix BioTherapeutics, Inc. QOC 8.6BIIBBiogen Inc.QOC 8.4IMCRImmunocore Holdings plcQOC 7.9TECHBio-Techne CorpQOC 7.8

Read investment analysis: EXEL · HALO · NBIX · GILD · PLX

See all Biological Products, (No Diagnostic Substances) stocks ranked →

Frequently Asked Questions About VivoSim Labs, Inc.

What is VivoSim Labs, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, VivoSim Labs, Inc. (VIVS) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $0.99. The Quality of Company score is 4.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is VIVS overvalued or undervalued right now?

At $0.85, 9 of 9 active models suggest VIVS may be undervalued, while 0 indicate potential overvaluation. The median of all 9 fair value estimates is $1.40, 63.8% above the current price of $0.85 — a consensus view that VIVS is undervalued. The assessment depends on which methodology best fits VivoSim Labs, Inc.'s business model in Biological Products, (No Diagnostic Substances).

What does a Quality of Company score of 4.5 mean for VIVS?

VivoSim Labs, Inc.'s QOC of 4.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on VIVS?

CirclFi analyzes VIVS with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 9 of 13 are active for this stock. Read the full methodology →

Is VIVS a value trap in 2026?

VivoSim Labs, Inc.'s Value Trap score is 51/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 9-model valuation engine, VivoSim Labs, Inc. (VIVS) has a median fair value of $1.40 — 63.8% above the current price of $0.85 — as of 2026-07-15.” Source: circlfi.com/stock/VIVS/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 9 mathematical frameworks give you clarity on VIVS.

Unlock All 9 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access